abc biopply is a CRO with its own specifically designed proprietary 3D cell culture platform 3D CoSeedis™.
abc biopply’s proprietary technology creates hundreds of miniature versions of patient organs in a laboratory setting, using both healthy and diseased tissues. Their innovative models bridge the gap in predictability between the lab and the clinic.
The company offers a comprehensive portfolio of validated service packages based on the proprietary 3D CoSeedis in chip communication technology™. Utilizing 3D CoSeedis humanized multi-organoid models™, as well as traditional monolayer models, they specialize in assay endpoints useful for drug discovery and pharmaceutical development.
22.02.2022
Double revenues for biotech startup Abc bioapply (startupticker.ch)
11.03.2021
Quadira Biosciences to use abc biopply’s 3D cell technology for antibody development (startupticker.ch)
No milestones
No Jobs
No videos and documents
No Awards
Website:
biopply.com/
Headquarter:
Solothurn
Foundation Date:
August 2017
Technology:
Sectors: